Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

QT prolongation interval

STB The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals Immunotoxicology Studies... [Pg.60]

Monitor for QT-interval prolongation and extrapyramidal side effects... [Pg.74]

Drugs with the potential to cause QT interval prolongation and torsades de pointes should be avoided or used with extreme caution in patients with other risk factors for torsades de pointes. [Pg.108]

Elevated plasma concentrations of QT interval-prolonging drugs due to drug interactions or absence of dose adjustment for organ dysfunction... [Pg.129]

Rapid intravenous infusion of torsades-inducing drugs Concomitant administration of more than one agent known to cause QT interval prolongation/torsades de pointes Possible genetic predisposition Previous history of drug-induced torsades de pointes... [Pg.129]

Vardenafil can cause QT-interval prolongation this effect in combination with certain anti-arrhythmic agents can lead to life-threatening arrhythmias. CYP, cytochrome P-450 isoenzyme. [Pg.785]

The sequence of cardiovascular signs as serum magnesium increases from 3 mEq/L to 15 mEq/L is hypotension, cutaneous vasodilation, QT-interval prolongation, bradycardia, primary heart block, nodal rhythms, bundle branch block, QRS- and then PR-interval prolongation, complete heart block, and asystole. [Pg.909]

De Ponti F, Poluzzi E, Montanaro N (2000) QT-interval prolongation by non-cardiac drugs lessons to be learned from recent experience. Em J Clin Pharmacol 56 1-18... [Pg.110]

Cisapride (Propulsid) Gastroesophagal reflux disease Cardiovascular (QT-interval prolongation, arrhythmias) 2000 [54]... [Pg.13]

Dubitsky, G.M. (2000) Clinically important QT interval prolongation with three antipsychotics thioridazine, pimozide, sertindole, FDA. [Pg.20]

Ideal for studying the dose-response relationship for QT interval prolongation taking into account all the pharmacological properties of a compound The dog model is one of the most widely used anesthetized rabbits (especially female rabbits) have also been proposed for high sensitivity It provides complementary information with respect to in vitro tests (activity of metabolites, measurement of plasma drug concentrations, calculation of the volume of distribution) Possibility to induce experimental TdP... [Pg.64]

Malik, M. and Camm, A.J. (2001) Evaluation of drug-induced QT interval prolongation implications for drug approval and labelling. Drug Safety, 24, 323-351. [Pg.81]

Malik, M. (2001) Problems of heart rate correction in assessment of drug-induced QT interval prolongation. Journal of Cardiovascular Electrophysiology, 12, 411—420. [Pg.83]

ICH Topic S7B - The Nonclinical Evaluation of the Potential for delayed Ventricular Repolarization QT Interval Prolongation) by Human Pharmaceuticals. E M EA. (2005)http // www.emea.europa.eu/pdfs /human/ich/ 042302en.pdf. (last accessed 2/25/2007). [Pg.85]

Netzer, R., Ebneth, A., BischofF, U. and Pongs, O. (2001) Screening lead compounds for QT interval prolongation. Drug Discovery Today, 6, 78-84. [Pg.85]

Finlayson, K., Witchel, H.J., McCulloch, J. and Sharkey, J. (2004) Acquired QT interval prolongation and HERG implications for drug discovery and development. European Journal of Pharmacology, 500, 129-142. [Pg.85]

Davis, A.S. (1998) The pre-clinical assessment of QT interval prolongation a comparison of in vitro and in vivo methods. Human el Experimental Toxicology, 17, 677-680. [Pg.85]

T. G. (2003) Relationships between predinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs evidence for a provisional safety margin in drug development. Cardiovascular Research, 58, 32-45. [Pg.86]

Gralinski, M.R. (2000) The assessment of potential for QT interval prolongation with new pharmaceuticals impact on drug development Journal of Pharmacological and Toxicological Methods, 43, 91-99. [Pg.87]

Fermini, B. and Fossa, A.A. (2003) The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Reviews. Drug Discovery, 2, 439—447. [Pg.123]

Interactions with the hERG cardiac channel leading to QT interval prolongation (e.g., some antipsychotics and antihistamines drugs)... [Pg.246]

CPMP. Points to Consider The assessment of QT interval prolongation by noncardiovascular medicinal products... [Pg.248]

ICH S7B Note for Guidance on the Non-clinical Evaluation for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals Describes a non-clinical testing strategy for assessing the potential of a test substance to slow ventricular repolarization. Includes information concerning non-clinical assays and integrated risk assessment Anon.42... [Pg.249]

Component elements of the testing strategy for assessing risk for delayed ventricular repolarization and QT interval prolongation. (Source Adapted from Anon., CPMP/ICH/423/02,2005.)... [Pg.258]

Anon., European Medicines Evaluation Agency, Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products, Points to Consider The assessment of QT interval prolongation by non-cardiovascular medicinal products, CPMP/986/96, London, December 17, 1997, http //www.emea.eu.int/pdfs/human/swp/098696en.pdf... [Pg.279]

See other pages where QT prolongation interval is mentioned: [Pg.480]    [Pg.486]    [Pg.129]    [Pg.301]    [Pg.1292]    [Pg.576]    [Pg.80]    [Pg.762]    [Pg.8]    [Pg.11]    [Pg.84]    [Pg.85]    [Pg.85]    [Pg.85]    [Pg.109]    [Pg.423]    [Pg.455]    [Pg.133]    [Pg.246]    [Pg.273]   
See also in sourсe #XX -- [ Pg.39 , Pg.255 ]

See also in sourсe #XX -- [ Pg.280 , Pg.302 ]

See also in sourсe #XX -- [ Pg.297 , Pg.352 ]

See also in sourсe #XX -- [ Pg.8 ]

See also in sourсe #XX -- [ Pg.34 ]

See also in sourсe #XX -- [ Pg.124 ]



SEARCH



Prolong

Prolonged

Prolonged QT interval

QT prolongation

QT prolongers

QT-interval prolongers

© 2024 chempedia.info